antibiotic susceptibility

RESTORES

bacterial virulence and

DEFEATS

QURETECH BIO – Home2019-12-13T13:51:13+00:00

SHORT FACTS

A laboratory image from Quretech Bio

We are addressing a significant unmet medical need by developing a new class of antibacterial agents that target antimicrobial resistance.

This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. The compounds are new small molecule chemical entities from a well-developed chemical platform with excellent synthetic availability and desirable drug properties.

Quretech Bio has an experienced team

THIS MEANS:

Developing new class of antibacterial agents that combat antibiotic resistance
New mode of action
Target large and growing markets
High unmet medical need
Experienced team

ABOUT QURETECH BIO

QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance, and to establish as a leading drug discovery company in the field.

The company was founded in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis, MO, USA. Since the foundation, several key persons have joined the company either as board members, researchers, or scientific advisors. Last year Quretech Bio received an institutional investment from Nordiska Centruminvest.

The Company’s development programs are based on research mainly funded by academic research grants. The company has also received soft funding from Umeå Biotech Incubator and the European Union Horizon 2020 program SME Instrument Phase 1 (grant agreement no. xxx).

Quretech Bio - Infografik about the company

LATEST NEWS

CONTACT

FILL IN THIS FORM

We are actively seeking investors and collaboration partners to enable development and commercialization of the company’s pipeline programs.

Welcome to contact us for more information about partnership opportunities.

Fredrik Almqvist, Quretech Bio

CEO
FREDRIK ALMQVIST

Annica Rönnbäck, Quretech Bio

Project Coordinator
ANNICA RÖNNBÄCK